# A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin

Study · id `cardio:ct-nct06192108` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06192108](<https://clinicaltrials.gov/study/NCT06192108>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06192108

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 962 participants.

## Technical summary

Registry record NCT06192108. Randomized; no masking; primary purpose treatment. Start 2024-01-10 (actual); primary completion 2025-09-26 (actual). Results posted on 2026-10-16.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 962 participants (enrolled count; ClinicalTrials.gov record NCT06192108, source copy `cardio:ctgov-nct06192108-2026-10-16`, retrieved 2026-10-26)
- Started: 2024-01-10 (actual) (ClinicalTrials.gov record NCT06192108, source copy `cardio:ctgov-nct06192108-2026-10-16`, retrieved 2026-10-26)
- Primary completion: 2025-09-26 (actual) (ClinicalTrials.gov record NCT06192108, source copy `cardio:ctgov-nct06192108-2026-10-16`, retrieved 2026-10-26)
- Completion: 2025-09-26 (actual) (ClinicalTrials.gov record NCT06192108, source copy `cardio:ctgov-nct06192108-2026-10-16`, retrieved 2026-10-26)
- Results first posted: 2026-10-16 (ClinicalTrials.gov record NCT06192108, source copy `cardio:ctgov-nct06192108-2026-10-16`, retrieved 2026-10-26)
- Countries: United States; China; Germany; Mexico; Poland; Taiwan (ClinicalTrials.gov record NCT06192108, source copy `cardio:ctgov-nct06192108-2026-10-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06192108-2026-10-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
- Acronym: ACHIEVE-2
- Condition: Type 2 Diabetes
- Intervention (Drug): Orforglipron
- Intervention (Drug): Dapagliflozin
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial (`cardio:pubmed-42259339`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d843e7e3e89930ac63453c68c3ca3e71f5a147e8041c8e15c39989b36d0c88f6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
